{'fraction_non_alphanumeric': 0.030927835051546393, 'fraction_numerical': 0.010309278350515464, 'mean_word_length': 5.406593406593407, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Bromazepam in the treatment of anxiety in nephrology and haemodialysis (author's transl)].

Bromazepam was tested in 15 patients with chronic renal failure undergoing haemodialysis and in 10 patients with normal renal function (controls). The initial dosage (6 mg/day) was modified according to anxiolytic response and sedative effects. Satisfactory results were obtained with 6 mg/day in patients under haemodialysis and in controls with reactional anxiety. Relief from anxiety-induced inhibitions and decrease in somatic disorders were observed. The drug was very well tolerated.